A Worldwide Survey on the Understanding of Psoriatic Disease Among Patients With Psoriasis and Psoriatic Arthritis

July 20, 2021 updated by: Novartis Pharmaceuticals

Psoriasis and Beyond: A Worldwide Survey on the Understanding of Psoriatic Disease Among Patients With Psoriasis and Psoriatic Arthritis

The study is a Worldwide Survey on the Understanding of Psoriatic Disease among Patients with Psoriasis and Psoriatic Arthritis.

Study Overview

Status

Completed

Conditions

Detailed Description

This is a cross-sectional, quantitative online survey of patients with psoriasis with or without concomitant psoriatic arthritis. Following assessment of participant eligibility via a 5-minute online screener, the 25-minute internet-based survey will be conducted without any follow-up.

Study Type

Observational

Enrollment (Actual)

4978

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Switzerland
      • Basel, Switzerland
        • Novartis Investigational Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 100 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

The study population will consist of adults with self-reported Psoriasis and/or Psoriatic Arthritis. Screening questions will be used to determine the eligibility for each respondent to the survey.

Description

Inclusion Criteria:

  1. Patients who self-report to have been diagnosed with Psoriasis or Psoriasis and Psoriatic Arthritis before or at the time of data collection
  2. Patients 18 years of age or older at the time of data collection
  3. Patients who did not participate in surveys regarding Psoriasis or Psoriatic Arthritis in the last 4 weeks
  4. Body Surface Area (BSA) of >5 to <10, with psoriasis affecting sensitive and/or prominent body parts: face, palms, hands, fingers, genitals, soles of feet or nails or a BSA of 10 and above, when psoriasis was at its worst

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Psoriasis and Psoriatic Arthritis
The study population consists of adults who self-report to have been diagnosed with psoriasis with or without concomitant psoriatic arthritis

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
A web-based survey will be answered by the participants. Data collected for the analysis of the primary objective include validated patient-reported outcomes (such as DLQI), as well as responses to non-validated questions.
Time Frame: 1 Day of survey
To assess patients' understanding of psoriasis and psoriatic arthritis as part of a systemic disease and the humanistic and physical burden of living with the condition.
1 Day of survey

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
A web-based survey will be answered by the participants. The data collected for the analysis of the secondary objectives include validated tools (such as PAM-13), as well as responses to non-validated questions.
Time Frame: 1 Day of Survey
To assess the patient's perceptions and attitudes related to the relationship with their physician, the patient journey through the healthcare system, as well as barriers to self-management, diagnosis, patient perceptions on biologics, treatment expectations, and satisfaction with care.
1 Day of Survey

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Novartis Pharmaceuticals

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

November 12, 2020

Primary Completion (ACTUAL)

June 3, 2021

Study Completion (ACTUAL)

June 3, 2021

Study Registration Dates

First Submitted

October 29, 2020

First Submitted That Met QC Criteria

November 3, 2020

First Posted (ACTUAL)

November 4, 2020

Study Record Updates

Last Update Posted (ACTUAL)

July 21, 2021

Last Update Submitted That Met QC Criteria

July 20, 2021

Last Verified

July 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CAIN457A2023

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Plaque Psoriasis, Psoriatic Arthritis

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe